A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma

Therapeutic strategies designed to target TP53-deficient cancer cells remain elusive. Here, we showed that TP53 loss initiated a pharmacologically actionable secretory process that drove lung adenocarcinoma (LUAD) progression. Molecular, biochemical, and cell biological studies showed that TP53 loss...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Tan, Xiaochao, Shi, Lei, Banerjee, Priyam, Liu, Xin, Guo, Hou-Fu, Yu, Jiang, Bota-Rabassedas, Neus, Rodriguez, B. Leticia, Gibbons, Don L., Russell, William K., Creighton, Chad J., Kurie, Jonathan M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7773359/
https://ncbi.nlm.nih.gov/pubmed/32931483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI137186
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados